TABLE 1.
Demographic and treatment characteristics of childhood cancer survivors and NHANES comparison group
| Characteristicsa | Survivors N=164 | NHANES N=584 | ||
|---|---|---|---|---|
| Female sex | 73 | (44.5) | 260 | (44.5) |
| Current age, years (median, range) | 28.9 | (16–38) | 28.0 | (15–39) |
| White/non-Hispanic race/ethnicity | 134 | (81.7) | 476 | (81.5) |
| Time since diagnosis, years (median, range) | 17.4 | (13–22) | - | - |
| Age at cancer diagnosis, years (median, range) | 11.3 | (0–20) | - | - |
| Cancer diagnosis | ||||
| Acute lymphoblastic leukemia | 75 | (45.7) | - | - |
| Lymphoblastic lymphoma | 22 | (13.4) | - | - |
| Hodgkin lymphoma | 58 | (35.4) | - | - |
| Osteosarcoma | 9 | (5.5) | - | - |
| Doxorubicin exposure | 164 | (100) | ||
| Cumulative doxorubicin dose, mg/m2 (median, range) | 300 | (100–600) | - | - |
| Cranial radiotherapy exposure | 97 | (59.1) | ||
| Chest radiotherapy exposure | 50 | (30.5) | - | - |
| Radiotherapy dose, Gy (median, range)b | 22.1 | (21.0–25.5) | - | - |
| Dexrazoxane exposure | 86 | (52.4) | ||
a
N (%) unless otherwise specified
b
Among exposed